Articlenpj drug discovery2026
Efficient and valid large molecule generation via self-supervised generative models.
Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The realm of molecular design, particularly for large molecules, presents unique challenges and opportunities in drug discovery and materials science. Large molecule design is inherently more complex and less explored compared to designing small molecules, adding significant difficulty in generative modeling. We aim to establish strong baselines for better scalability, efficiency, and generative performance in this domain. We evaluate the scalability and performance of generative AI models, initially effective for small molecule design, in generating large molecules for potential drugs in gene-based therapies, immunotherapies, hormonal regulators, and targeted cancer therapies. Our findings indicate that computational strategies and model architectures designed for small molecules may not readily extend to large molecular structures. To address these limitations, we explore masked language modeling strategies alongside advanced tokenization methods, including Atom-Pair Encoding (APE), to enhance generative AI models. We probe how incorporating such strategies, particularly the APE tokenization method that explicitly captures structural and chemical characteristics, can significantly improve design capabilities for complex molecular structures. Overall, our results demonstrate both the potential and challenges of deep generative modeling for large molecules and how the proposed enhancements may bridge the gap in generating large molecules when novel discovery is the ultimate goal.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.